MFWM
BMRN icon

Motley Fool Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Motley Fool Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14M Sell
247,877
-82,976
-25% -$4.84M 1.58% 20
2025
Q4 		$19.7M Sell
330,853
-85,023
-20% -$4.63M 1.53% 16
2025
Q3 		$22.5M Sell
415,876
-60,073
-13% -$3.44M 1.53% 16
2025
Q2 		$26.2M Buy
475,949
+126,970
+36% +$7.48M 1.58% 14
2025
Q1 		$24.7M Buy
348,979
+1,251
+0.4% +$84.2K 1.46% 18
2024
Q4 		$22.7M Sell
347,728
-76,869
-18% -$5.15M 1.17% 21
2024
Q3 		$29.8M Sell
424,597
-21,106
-5% -$1.76M 1.5% 15
2024
Q2 		$36.7M Sell
445,703
-13,032
-3% -$1.08M 1.87% 13
2024
Q1 		$40.1M Sell
458,735
-11,554
-2% -$1.03M 2.07% 11
2023
Q4 		$45.4M Sell
470,289
-18,667
-4% -$1.65M 2.38% 10
2023
Q3 		$43.3M Buy
488,956
+159,421
+48% +$14.2M 2.5% 9
2023
Q2 		$28.6M Sell
329,535
-7,271
-2% -$684K 1.68% 16
2023
Q1 		$32.8M Sell
336,806
-1,836
-0.5% -$190K 2.05% 14
2022
Q4 		$35M Sell
338,642
-4,247
-1% -$399K 2.43% 8
2022
Q3 		$29.1M Sell
342,889
-6,100
-2% -$543K 1.9% 14
2022
Q2 		$28.9M Sell
348,989
-8,001
-2% -$637K 1.82% 16
2022
Q1 		$27.5M Buy
356,990
+128,822
+56% +$10.8M 1.31% 23
2021
Q4 		$20.2M Sell
228,168
-5,535
-2% -$457K 0.88% 38
2021
Q3 		$18.1M Sell
233,703
-6,807
-3% -$537K 0.79% 43
2021
Q2 		$20.1M Sell
240,510
-3,811
-2% -$302K 0.84% 41
2021
Q1 		$18.4M Sell
244,321
-2,560
-1% -$209K 0.83% 43
2020
Q4 		$21.6M Buy
246,881
+1,792
+0.7% +$142K 0.96% 37
2020
Q3 		$18.6M Buy
245,089
+1,528
+0.6% +$155K 0.97% 32
2020
Q2 		$30M Sell
243,561
-7,188
-3% -$714K 1.71% 12
2020
Q1 		$21.2M Sell
250,749
-12,511
-5% -$1.08M 1.53% 19
2019
Q4 		$22.3M Buy
+263,260
New +$19.9M 1.34% 21

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Motley Fool Wealth Management's BMRN Position: Q1 2026 in Review

Motley Fool Wealth Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 25% in Q1 2026, selling an estimated $4.84M and leaving 247,877 shares worth $14M. The position accounts for 1.58% of the portfolio, ranked #20.

Motley Fool Wealth Management first reported a position in BMRN in Q4 2019 and has held it in 26 quarters since. The position peaked at $45.4M in Q4 2023. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Motley Fool Wealth Management held 247,877 shares of BioMarin Pharmaceuticals worth $14M as of Q1 2026.
  • Motley Fool Wealth Management sold 82,976 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $4.84M.
  • BioMarin Pharmaceuticals made up 1.58% of Motley Fool Wealth Management's portfolio in Q1 2026, its #20 holding.
  • Motley Fool Wealth Management first reported a position in BioMarin Pharmaceuticals in Q4 2019 and has held it in 26 quarters since.
  • Motley Fool Wealth Management's BioMarin Pharmaceuticals position peaked at $45.4M in Q4 2023.
  • 555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Motley Fool Wealth Management's 13F filing for Q1 2026, filed 12 May 2026.